Table 6.

The total mean score of the ocular adverse events per injection observed in each group

Week/Visit	Total mean score of the adverse events		p value
	Brolucizumab arm n = 56	Aflibercept arm n = 58
Week 0	0.73 ± 0.70	0.64 ± 0.58	0.44
Week 4	0.68 ± 0.54	0.66 ± 0.61	0.83
Week 8	0.80 ± 0.82	0.69 ± 0.71	0.43
Week 12	0.02 ± 0.13	0.07 ± 0.26	0.18
Week 16	0.04 ± 0.19	0.43 ± 0.62	< 0.0001*
Week 20	0.18 ± 0.54	0.40 ± 0.62	0.04*
Week 24	0.40 ± 0.68	0.35 ± 0.58	0.68
Week 28	0.26 ± 0.56	0.43 ± 0.63	0.14
Week 32	0.33 ± 0.67	0.45 ± 0.63	0.36
Week 36	0.24 ± 0.47	0.48 ± 0.66	0.03*
Week 40	0.20 ± 0.63	0.32 ± 0.54	0.30
Week 44	0.20 ± 0.45	0.33 ± 0.47	0.17
Week 48	0.07 ± 0.26	0.31 ± 0.47	0.002*

Data presented as mean ± standard deviation

*p-value < 0.05 for the t-test considered significant

Score 0: No adverse events; Score 1: Subconjunctival haemorrhage, Pain not requiring oral NSAIDs; Score 2: Anterior chamber (AC) cells and flare less than or equal to two. No circumciliary congestion. Ocular pain requiring oral NSAID; Score 3: AC cells and flare more than two, circumciliary congestion, vitritis grade 1. Patient not requiring oral steroids for management; Score 4: Hypopyon in AC, synechiae formation, vitritis more than grade 2, optic disc oedema/hyperaemia, retinal vascular sheathing/haemorrhages in retina in addition to pre-existing choroidal neovascularization.